| Autor: |
Mitkowski P; 1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland., Witkowski A; Department of Interventional Cardiology and Angiology, National Institute of Cardiology in Warsaw, Warsaw, Poland., Szymański P; Clinical Cardiology Center, National Institute of Medicine MSWiA, Warsaw, Poland.; Department of Invasive Cardiology, Center for Postgraduate Medical Education, Warsaw, Poland., Gierlotka M; Department of Cardiology, Institute of Medical Sciences, University of Opole, Opole, Poland., Gil R; Department of Cardiology, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland. |
| Jazyk: |
angličtina |
| Zdroj: |
Cardiovascular research [Cardiovasc Res] 2024 Jul 31; Vol. 120 (9), pp. e39-e40. |
| DOI: |
10.1093/cvr/cvae114 |
| Abstrakt: |
Competing Interests: Conflict of interest: Przemyslaw Mitkowski: speaker fees, advisory board fees: Abbott, Amgen, AstraZeneca, Biotronik, Boehringer-Ingelheim, Boston Scientific, Bristol Myers Squibb, Medtronic, Novartis, Pfizer, Sanofi Servier; Research Contracts: Abbott, Biomed Orchestra, Biotronik, Medtronic; Adam Witkowski: speakers fee: Novartis, advisory fees: Novartis; Piotr Szymański: speakers fees from Novartis and Samsung; Robert Gil: speakers fee: Novartis, Amgen, Pfizer, Sandoz, advisory board fee: Novartis, Novo Nordisk, Medtronic. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
